Filing Flows › Alamar Biosciences (ALMR) › Q2 2026
Alamar Biosciences (ALMR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
Alamar Biosciences (ALMR) reported revenue of $29.4M for the second quarter 2026 (Q2 2026), +82% from a year earlier and +13% from the quarter before. Operating margin was -46.0%, net loss $13.2M (44.9% of revenue).
Alamar Biosciences, Q2 2026: revenue $29.4M (+82% year over year), operating margin -46.0%, net loss $13.2M, operating cash flow −$11.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29.4M | +13% | +82% |
| Operating profit | −$13.5M | — | — |
| Net earnings | −$13.2M | — | — |
| Operating cash flow | −$11.3M | — | — |
What changed
Revenue was $29.4M in Q2 2026, up 82% year over year and up 13% from the previous quarter. Consumables was the largest line at 53% of revenue. Consumables added $9.2M year over year (up 147%), 69% of the total change.
Gross margin was 60.2%, up 7.1 points from a year earlier. Operating costs exceeded revenue by $13.5M, an operating margin of -46.0%. Operating expenses grew 89% against revenue growth of 82%. The fastest-growing cost line was SG&A (+129%). The quarter ended with a net loss of $13.2M, narrower than the previous quarter's $21.3M loss.
Operating cash flow was −$11.3M. Non-cash charges added back $1.1M of depreciation and amortization and $3.3M of share-based compensation. Working capital and other items used $2.5M. Capital expenditures of $3.6M exceeded it, leaving free cash flow of −$15.0M.
Questions
What was Alamar Biosciences' revenue in the second quarter 2026?
Alamar Biosciences (ALMR) reported revenue of $29.4M for the second quarter 2026 (Q2 2026), +82% from a year earlier and +13% from the quarter before.
Was Alamar Biosciences profitable in the second quarter 2026?
Operating loss was $13.5M (-46.0% of revenue) and net loss $13.2M.
Source: Alamar Biosciences 10-Q on SEC EDGAR.